Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Critical reviews in oncology/hematology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2015.09.003PMID 26454471
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen

  2015cited by this paper
• Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.

  2015cited by this paper
• Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

  2015cited by this paper
• Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.

  2015cited by this paper
• Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia

  2015cited by this paper
• Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

  2015cited by this paper
• Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia.

  2015cited by this paper
• High level of full‐length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

  2015cited by this paper
• Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.

  2014cited by this paper
• Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective

  2014cited by this paper
• Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

  2014cited by this paper
• Incorporating targeted agents into future therapy of chronic lymphocytic leukemia.

  2014cited by this paper
• Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages

  2014cited by this paper
• Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors

  2014cited by this paper
• A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  2014cited by this paper
• Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

  2014cited by this paper
• Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia

  2014cited by this paper
• Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.

  2014cited by this paper
• Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.

  2014cited by this paper
• Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells

  2014cited by this paper
• Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion

  2014cited by this paper
• How does lenalidomide target the chronic lymphocytic leukemia microenvironment?

  2014cited by this paper
• Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease

  2014cited by this paper
• Long‐term follow‐up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia

  2014cited by this paper
• Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials

  2014cited by this paper
• Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia.

  2014cited by this paper
• A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.

  2014cited by this paper
• Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

  2014cited by this paper
• Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications

  2014cited by this paper
• Early Results Of a Phase II Study Of Lenalidomide and Rituximab As Frontline Treatment Of Patients With Chronic Lymphocytic Leukemia

  2013cited by this paper
• Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

  2013cited by this paper
• Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.

  2013cited by this paper
• Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

  2013cited by this paper
• Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity

  2013cited by this paper
• Lenalidomide and Chronic Lymphocytic Leukemia

  2013cited by this paper
• Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

  2013cited by this paper
• Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

  2013cited by this paper
• Tumor-induced host immunosuppression: special focus on CLL.

  2013cited by this paper
• Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages?

  2013cited by this paper
• High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone

  2013cited by this paper
• Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

  2013cited by this paper
• Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.

  2013cited by this paper
• Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).

  2013cited by this paper
• Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.

  2013cited by this paper
• Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.

  2013cited by this paper
• Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

  2012cited by this paper
• Fludarabine, Rituximab, and Lenalidomide in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): A Phase I/II Trial of the Sarah Cannon Research Institute

  2012cited by this paper
• Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells

  2012cited by this paper
• Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.

  2012cited by this paper
• Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.

  2012cited by this paper
• Stromal Endothelial Cells Establish a Bidirectional Crosstalk with Chronic Lymphocytic Leukemia Cells through the TNF-Related Factors BAFF, APRIL, and CD40L

  2012cited by this paper
• RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.

  2012cited by this paper
• Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression

  2012cited by this paper
• Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response

  2012cited by this paper
• Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.

  2012cited by this paper
• GSK-3 Spatial Regulation Has an Essential Role in Lenalidomide Activity and Represents a Biomarker of Clinical Response in CLL

  2012cited by this paper
• Angiogenic factors in chronic lymphocytic leukemia.

  2012cited by this paper
• Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

  2011cited by this paper
• Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease.

  2011cited by this paper
• Genomic and phenotypic characterization of nurse-like cells that promote drug resistance in chronic lymphocytic leukemia

  2011cited by this paper
• Impact of Lenalidomide on Gene Expression Profiles of Malignant and Immune Cells in Patients with Chronic Lymphocytic Leukemia

  2011cited by this paper
• Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia

  2011cited by this paper
• Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia

  2011cited by this paper
• Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response

  2011cited by this paper
• Nurse‐like cells show deregulated expression of genes involved in immunocompetence

  2011cited by this paper
• Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

  2011cited by this paper
• Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia

  2011cited by this paper
• BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

  2011cited by this paper
• The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.

  2011cited by this paper
• Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

  2011cited by this paper
• Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells

  2010cited by this paper
• Identification of a Primary Target of Thalidomide Teratogenicity

  2010cited by this paper
• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  2010cited by this paper
• A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL

  2010cited by this paper
• Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide

  2010cited by this paper
• CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

  2010cited by this paper
• Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

  2010cited by this paper
• Eμ-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction

  2009cited by this paper
• Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.

  2009cited by this paper
• The humanized CD40 antibody SGN‐40 demonstrates pre‐clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia

  2009cited by this paper
• Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

  2009cited by this paper
• HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer

  2009cited by this paper
• Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

  2008cited by this paper
• Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.

  2008cited by this paper
• Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.

  2008cited by this paper
• Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

  2008cited by this paper
• Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

  2008cited by this paper
• Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia.

  2007cited by this paper
• Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients

  2007cited by this paper
• Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

  2006cited by this paper
• Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

  2005cited by this paper
• Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia.

  2002cited by this paper
• CD4+CD25high Regulatory Cells in Human Peripheral Blood1

  2001cited by this paper
• Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.

  2000cited by this paper
• Acquired CD40-ligand deficiency in chronic lymphocytic leukemia

  1997cited by this paper
• In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell Proliferation

  1997cited by this paper
• In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation.

  1997cited by this paper

• IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK

  2021cites this paper
• Solubility and thermodynamic properties of hydrate lenalidomide in phosphoric acid solution

  2021cites this paper
• Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.

  2019cites this paper
• Pre-clinical development of novel ROR1 chimeric antigen receptor T cells and bispecific T cell engagers

  2018cites this paper
• LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia

  2018cites this paper
• Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide

  2018cites this paper
• IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML

  2018cites this paper
• Targeting the crosstalk between tumor cells and microenvironment: a new therapeutic approach for the treatment of lymphoid neoplasms

  2017cites this paper
• Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia

  2017cites this paper
• Recent advances in therapy of chronic lymphocytic leukaemia

  2016cites this paper
• Lenalidomide in chronic lymphocytic leukemia

  2016influential citation
• SCUOLA DI DOTTORATO DI RICERCA IN ONCOLOGIA E ONCOLOGIA CHIRURGICA XXVIII CICLO LEUKEMIC CELL/MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: ROLE OF JAK/STAT AXIS IN THE SURVIVAL OF NEOPLASTIC CLONE Direttore della Scuola: Ch.ma Prof.ssa PAOLA ZANOVELLO Supervisore: Dott.ssa MONICA F

  2016cites this paper
• Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints

  2016cites this paper
• Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia

  2016cites this paper